Prostate transmembrane androgen inducible protein 1 (PMEPA1): regulation and clinical implications

Qicui Zhu; Yue Wang; Yaqian Liu; Xiaoke Yang; Zongwen Shuai

doi:10.3389/fonc.2023.1298660

Prostate transmembrane androgen inducible protein 1 (PMEPA1): regulation and clinical implications

Front Oncol. 2023 Dec 20:13:1298660. doi: 10.3389/fonc.2023.1298660. eCollection 2023.

Authors

Qicui Zhu^#¹, Yue Wang^#¹, Yaqian Liu¹, Xiaoke Yang¹, Zongwen Shuai^{1

2}

Affiliations

¹ Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
² Inflammation and Immune Mediated Diseases Laboratory of Anhui, Hefei, China.

^# Contributed equally.

Abstract

Prostate transmembrane androgen inducible protein 1 (PMEPA1) can promote or inhibit prostate cancer cell growth based on the cancer cell response to the androgen receptor (AR). Further, it can be upregulated by transforming growth factor (TGF), which downregulates transforming growth factor-β (TGF-β) signaling by interfering with R-Smad phosphorylation to facilitate TGF-β receptor degradation. Studies have indicated the increased expression of PMEPA1 in some solid tumors and its functioning as a regulator of multiple signaling pathways. This review highlights the multiple potential signaling pathways associated with PMEPA1 and the role of the PMEPA1 gene in regulating prognosis, including transcriptional regulation and epithelial mesenchymal transition (EMT). Moreover, the relevant implications in and outside tumors, for example, as a biomarker and its potential functions in lysosomes have also been discussed.

Keywords: Epithelial-mesenchymal transition (EMT); biomarker; lysosome; prostate transmembrane androgen-inducible protein 1 (PMEPA1); transcriptional regulation.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China, Grant/Award Number: 81871296.